Semaglutide and Tirzepatide Drive 15-20% Weight Loss, Offer Broad Cardiometabolic Benefits

Historically, managing obesity has been challenging, with many medications withdrawn due to safety concerns. This created a significant gap in effective, well-tolerated treatments. However, a deeper scientific understanding of mechanisms regulating appetite and energy balance has paved the way for a new generation of pharmacotherapies. These novel agents, particularly incretin analogs, aim to provide both substantial weight reduction and broader cardiometabolic benefits, addressing the multifaceted nature of obesity-related comorbidities.

This narrative review synthesized current evidence on Food and Drug Administration-approved medications and emerging investigational agents for obesity management. The authors provided an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents. The review focused on the evolution of therapeutic options, highlighting the shift towards medications with improved safety and efficacy profiles, particularly the injectable incretin analogs like semaglutide and tirzepatide.

The review highlights that current injectable incretin analogs, specifically semaglutide and tirzepatide, are associated with substantial mean weight loss. Patients typically experience weight reductions in the range of 15%-20% over approximately 12-18 months. Beyond weight loss, these agents confer significant cardiometabolic benefits, including reductions in adverse cardiovascular and kidney outcomes. They also demonstrate improvements across several key markers:

Improvements were observed in glycaemia, blood pressure, lipid profile, and steatohepatitis, underscoring their broad therapeutic impact. This comprehensive benefit profile positions these medications as critical tools in managing not just obesity, but also its associated metabolic complications.